Navigation Links
Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
Date:10/3/2007

p>"These findings provide further evidence of the role of IL-12/23 in the pathogenesis of psoriasis and the promise that a new therapeutic approach like ustekinumab may hold for dermatologists and their patients living with this chronic, immune-related disease," said Craig Leonardi, MD, St. Louis University Medical School and lead investigator of the study. "The efficacy and safety data for ustekinumab in the treatment of psoriasis are exciting for the dermatology community."

At week 12 of this Phase 3, multicenter, randomized, double-blind, placebo-controlled trial, 67 percent of patients treated with 45 mg ustekinumab (two 45 mg doses four weeks apart) and 76 percent of patients treated with 90 mg ustekinumab (two 90 mg doses four weeks apart), achieved PASI 75 compared with four percent of patients receiving placebo (P < 0.001 for each comparison versus placebo). Also at week 12, 42 percent of patients in the 45 mg ustekinumab dosing group and 51 percent of patients in the 90 mg ustekinumab dosing group achieved PASI 90, or nearly complete clearance of psoriasis, compared with one percent of patients receiving placebo (P < 0.001 for each comparison versus placebo). Similar response rates were observed in the placebo group 12 weeks after crossover to treatment with ustekinumab. After one additional dose at week 16, responses were maintained through week 28, which is consistent with the maintenance regimen of every 12-week dosing currently being evaluated in the Phase 3 program. Improvements in clinical measures were paralleled with improvements in quality of life measures.

"These findings show that by targeting IL-12/23 with ustekinumab, we may be able to offer dermatologists and patients a new, promising biologic therapy with an infrequent dosing regimen for the treatment of psoriasis," said Jerome A. Boscia, MD, senior vice president, Clinical Research and Development, Centocor, Inc. "We are encouraged by the results from the Phase 3 program and look
'/>"/>

SOURCE Centocor, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
5. Antisense Pharma: Promising Phase IIb Results of Targeted Therapy with AP 12009 in Recurrent Anaplastic Astrocytoma
6. Promising Data on Cognitive Effects of Safinamide in Early Parkinsons Disease
7. Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
8. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
9. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
10. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
11. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... -- Landauer, Inc. (NYSE: LDR ), a recognized ... outsourced medical physics services and high quality medical consumable ... its President and Chief Executive Officer, will be stepping ... a member of the Board of Directors, effective as ... an interim basis by Michael T. Leatherman , ...
(Date:8/21/2014)... GREENWICH, Conn. , Aug. 21, 2014 /PRNewswire/ ... West Lafayette, Indiana , has ... determination and characterization of small and large molecules, ... addition of the Bruker maXisPlus Q-TOF mass spectrometer. ... Jonathan Goldman , CEO, Aptuit, said, "The expanded ...
(Date:8/21/2014)... DEERFIELD, Ill. , Aug. 21, 2014 /PRNewswire/ ... reports Baxter International Inc. today announced positive results ... BAX 855, an investigational, extended half-life recombinant factor ... ADVATE [Antihemophilic Factor (Recombinant)], which met its primary ... the prophylaxis arm compared to the on-demand arm. ...
Breaking Medicine Technology:Landauer, Inc. Announces Executive Management Change 2Aptuit SSCI Adds Ultra High Resolution Q-TOF Mass Spectrometer for Large & Small Molecule Analyses 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5
... , LONDON , January 19 The ... later today. , The ShelterBox Response Team of David ... have been in Haiti,s capital since Thursday, took,delivery of the first ShelterBoxes ... twelve of these boxes will be used to build an emergency,field hospital at the ...
... , THE WOODLANDS, Texas , Jan. 19 ... changing its name to the Life Beyond Cancer Foundation. This new ... to provide to cancer patients and their families. , The ... removing barriers to prevention, education, early detection, treatment and survivorship. Cancer ...
Cached Medicine Technology:First ShelterBoxes Arrive in Port au Prince - Pictures and Footage 2US Oncology Foundation Becomes Life Beyond Cancer Foundation 2US Oncology Foundation Becomes Life Beyond Cancer Foundation 3
(Date:8/22/2014)... A new study of self-awareness by Kessler ... (MS) may be able to improve their self-awareness ... ahead of print on July 2 in ... Nancy D. Chiaravalloti & John DeLuca: Metacognitive knowledge ... doi: 10.3233/NRE-141113). Self-awareness is one,s ability to recognize ...
(Date:8/22/2014)... attained the distinguished Magnet hospital designation by the ... Considered the gold standard for nursing excellence, the ... professionalism. It is the top international credential for ... Newport Hospital was based on the hospital,s continued ... , "It is a privilege for us to ...
(Date:8/22/2014)... Counseling may do little to help young people with ... 66 studies that included nearly 18,000 people 25 and ... drinking problems. Participants in 49 studies attended a single ... the studies attended group sessions or a mix of ... motivational interviewing was used in the studies. This technique ...
(Date:8/22/2014)... treatments have become available for key subtypes of ... treatments can be pre-identified by looking for defined ... whose lung cancer is driven by rearrangement of ... drug crizotinib, which targets this abnormality. Many ongoing ... success by matching different drugs with specific subtypes ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 ItsHot.com, a ... now offering 60-80% off on its range of beautiful ... the purchase of Gold Hearts 14K White Rose Gold ... a discount of 77%. Previously priced at $3,715.00, ... $859.00. The item code of this mesmerizing pendant embedded ...
Breaking Medicine News(10 mins):Health News:Kessler Foundation study of self-awareness in MS has implications for rehabilitation 2Health News:Newport Hospital receives nursing's highest credential for third time with Magnet recognition 2Health News:Counseling Does Little to Deter Youth Drinking, Review Finds 2Health News:Online screening for rare lung cancer subtypes opens door to new kind of clinical trial 2Health News:Online screening for rare lung cancer subtypes opens door to new kind of clinical trial 3Health News:Online screening for rare lung cancer subtypes opens door to new kind of clinical trial 4Health News:ItsHot.com Now Offers 60-80% Discount on its Striking Collection of Diamond Heart Pendants 2
... new study reveals that almost two-thirds of US ... life, but very few of them experience post-traumatic ... emotional resilience in children, but it also suggests that ... adults, said William Copeland of Duke University Medical Center, ...
... Mayfield Dairy Farms announced today that it is voluntarily recalling ... a code date of 4/11/08 and a UPC code ... contains peanuts, which are not listed on the label. No ... ,Some individuals with allergies to peanuts run the ...
... Higher Colon Cancer Risk in Uveal Melanoma Patients and ... by Frederick H. Davidorf, MD, during the Association ... Meeting in Fort Lauderdale, Fla. ,The presentation ... p.m. to 4:45 p.m. in Hall B/C of the ...
... brown widow spider, a cousin to the well-known black widow, ... ,It is belongs to a group that is officially ... referred to as "fiddleback" spiders or "violin" spiders because of ... (fused head and thorax). ,The spiders are generally ...
... to over 76.6 million people over the age of 60. ... ministry, the country has 76,622,321 persons aged 60 and above. ... Uttar Pradesh tops the chart with 11.6 million elderly. ... has 5.7 million, Bihar and Tamil Nadu have 5.5 million ...
... Ministry of External Affairs, informed the Lok Sabha today that ... passports. ,At first these passports will be ... the end of 2007. Based on the experience gained from this ... the ordinary category by the end of 2008. , ...
Cached Medicine News:Health News:Two-thirds of US Children Experience Trauma, but Recover Fast 2Health News:Louisiana Residents Warned Against Brown Recluse Spiders 2
The CSV-1000ETDRS10% test face presents the standard ETDRS test at a contrast level of 10%. This test is widely used in clinical studies for the evaluation of refractive surgery and contact lenses....
... The CSV-1000S test face is widely used ... evaluation. This test presents standard visual acuity from ... (6 and 12 cycles/degree) and a real-world driver's ... cataract documentation as it provides a standard acuity ...
Contrast sensitivity testing, glare sensitivity testing and ETDRS acuity testing are provided in the self standardized CSV-1000 instrument. Patented photocell circuitry automatically monitors and cal...
... those involved with healthcare decisions to keep ... evidence in their field of interest - ... as the volume of evidence increases. Cochrane ... best single source available for continually updated ...
Medicine Products: